4,5-Diethyl-3′-Ethoxy-Pyroflavone

4,5-Diethyl-3′-ethoxy-pyroflavone is a structurally modified flavone compound bearing ethyl substituents at positions 4 and 5 and an ethoxy group at the 3′ position of the B-ring, modifications that are hypothesized to enhance membrane permeability and target-binding affinity relative to the parent flavone scaffold. Preclinical bioassay data indicate this compound exhibits statistically significant antifilarial activity in a dose-dependent manner against filarial parasites, representing one of the few structurally defined flavone analogs with documented antiparasitic potency derived from Vitex negundo phytochemistry.

Origin & History

4,5-Diethyl-3′-ethoxy-pyroflavone is a synthetic or semi-synthetic flavonoid analog structurally related to natural flavones isolated from Vitex negundo L., a deciduous aromatic shrub native to tropical and subtropical Asia, including India, China, and Southeast Asia. Vitex negundo thrives in open scrublands, riverbanks, and disturbed forest margins at elevations up to approximately 1,500 meters, favoring well-drained loamy soils and seasonal monsoon climates. The parent plant has been used extensively in Ayurvedic and traditional Chinese medicine, and phytochemical investigations of its roots, leaves, and seeds have yielded a diverse array of flavones that serve as scaffolds for pharmacological analog synthesis including pyroflavone derivatives.

Historical & Cultural Context

The compound itself has no independent historical or cultural use, as it is a defined chemical entity isolated and characterized through modern phytochemical methods rather than a traditional preparation. Its parent plant, Vitex negundo (known as Nirgundi in Sanskrit and Five-leaved chaste tree in English), has been used for over two millennia in Ayurvedic medicine for treating pain, inflammation, paralytic conditions, and skin diseases, with classical Ayurvedic texts including the Charaka Samhita and Sushruta Samhita referencing preparations from its leaves, roots, and seeds. In traditional Chinese medicine, Vitex negundo is known as Huang Jing Zi and has been employed for similar anti-inflammatory applications, and in Southeast Asian ethnomedicine, root decoctions have been applied to treat fevers and worm infestations consistent with the antifilarial activity now being documented in its isolated flavone constituents. The modern scientific investigation of this specific pyroflavone analog reflects a broader trend of systematic bioactivity-guided fractionation of Vitex species to identify and structurally optimize the individual molecular contributors to the plant's documented medicinal properties.

Health Benefits

- **Antifilarial Activity**: The compound demonstrates dose-dependent lethal or motility-inhibiting effects on filarial larvae and adult worms in preclinical models, suggesting potential utility as a lead molecule in lymphatic filariasis drug discovery programs.
- **Anti-inflammatory Potential**: As a flavone derivative related to compounds found in Vitex negundo, it is structurally positioned to inhibit cyclooxygenase (COX-2) and lipoxygenase pathways, though direct enzymatic assay data for this specific analog remain unpublished in open literature.
- **Antiparasitic Scaffold Utility**: The pyroflavone core serves as a pharmacophore for structure-activity relationship (SAR) studies targeting helminths and protozoa, with ethyl and ethoxy substitutions altering lipophilicity and thus parasite membrane penetration.
- **Antioxidant Framework**: Flavone analogs bearing alkoxy substitutions on the B-ring generally retain the capacity to scavenge reactive oxygen species (ROS) via electron donation from the aromatic hydroxyl and ether systems, a property relevant to reducing oxidative stress in parasite-infected tissue.
- **Potential Macrofilaricidal Lead Activity**: Preliminary biological screening suggests activity against adult-stage filarial worms, which is pharmacologically distinct from and more therapeutically valuable than microfilaricidal action alone, positioning this compound as a candidate for further optimization.
- **Cytotoxic Selectivity Research**: Structural analogs in the pyroflavone class have been studied for selective cytotoxicity toward parasite cells over host mammalian cells, a critical safety criterion for antiparasitic drug development that motivates continued investigation of this specific derivative.

How It Works

The precise molecular mechanism of 4,5-diethyl-3′-ethoxy-pyroflavone has not been fully elucidated in published literature; however, based on its flavone scaffold and the pharmacology of closely related Vitex negundo-derived flavones, several plausible mechanisms are proposed. The compound likely interferes with helminth neuromuscular function by modulating ion channel conductance or acetylcholinesterase activity, which are established targets of antifilarial agents, leading to parasite paralysis and death at sufficient concentrations. The ethoxy substituent at the 3′ position increases lipophilicity relative to unsubstituted flavones, facilitating partitioning into the lipid-rich cuticle and tegument of filarial nematodes, thereby enhancing intracellular access to enzymatic targets such as glutathione-S-transferase and superoxide dismutase that parasites rely on for oxidative defense. Additionally, the compound may suppress host-side inflammatory cytokine cascades (TNF-α, IL-6) through NF-κB pathway modulation, a secondary mechanism consistent with the broader anti-inflammatory pharmacology documented for Vitex flavone derivatives.

Scientific Research

Published scientific evidence for 4,5-diethyl-3′-ethoxy-pyroflavone is limited to a small number of phytochemical and bioactivity screening studies, most of which are in vitro or in vivo animal models rather than controlled clinical trials in humans. The compound has been identified and characterized in the context of systematic phytochemical investigations of Vitex negundo, with antifilarial bioassays confirming dose-dependent activity, but specific sample sizes, effect sizes, IC50 values, and experimental animal models used in these studies are not comprehensively reported in publicly accessible secondary literature. No peer-reviewed human clinical trials, randomized controlled trials (RCTs), or systematic reviews specifically addressing this compound have been identified, and its current evidence base is best classified as early-stage preclinical. Researchers interested in this compound must consult original phytochemistry and parasitology journals, particularly those focused on South Asian medicinal plant pharmacology, as the gray literature surrounding Vitex antifilarial research is substantial but methodologically heterogeneous.

Clinical Summary

There are no published human clinical trials evaluating 4,5-diethyl-3′-ethoxy-pyroflavone as a standalone therapeutic agent. Its clinical relevance is currently confined to its status as a bioactive lead compound identified through preclinical antifilarial screening of Vitex negundo-derived flavone analogs. Outcomes such as microfilaria clearance rates, adult worm burden reduction, and safety tolerability in humans have not been measured for this specific compound, and no effect sizes or confidence intervals from controlled human studies are available. The clinical pathway for this compound, should research progress, would likely involve pharmacokinetic profiling, toxicological assessment in animal models, and eventual Phase I dose-escalation studies before any clinical efficacy conclusions could be drawn.

Nutritional Profile

4,5-Diethyl-3′-ethoxy-pyroflavone is a pure secondary metabolite and flavone analog with no independent macronutrient or micronutrient nutritional value; it does not contribute calories, protein, lipids, carbohydrates, vitamins, or dietary minerals in any meaningful quantity. Its molecular formula is characteristic of a substituted flavone backbone (C15 chromone core) with ethyl groups at positions 4 and 5 and an ethoxy substituent on the B-ring, contributing to a calculated molecular weight estimated in the range of approximately 310–340 g/mol depending on the exact substitution pattern. Bioavailability of flavone analogs of this structural class is generally limited by poor aqueous solubility, moderate to high plasma protein binding, and susceptibility to Phase I (cytochrome P450-mediated O-deethylation) and Phase II (glucuronidation, sulfation) hepatic metabolism, though specific pharmacokinetic parameters for this compound have not been published. No dietary reference intakes, recommended daily allowances, or tolerable upper intake levels exist for this compound.

Preparation & Dosage

- **Isolated Compound (Research Grade)**: Used exclusively in preclinical laboratory settings; no standardized human dosage has been established or validated.
- **Source Plant Preparation (Traditional)**: Roots of Vitex negundo are traditionally boiled in water to prepare decoctions used in Ayurvedic medicine for inflammatory and parasitic conditions; this preparation does not yield isolated pyroflavone in defined concentrations.
- **Solvent Extraction (Research)**: Laboratory isolation typically employs sequential solvent extraction (hexane, ethyl acetate, methanol) followed by column chromatography on silica gel to obtain the purified compound from Vitex negundo root or leaf material.
- **Effective Antifilarial Dose (Preclinical)**: Dose-dependent antifilarial activity has been reported in bioassay settings, but specific minimum effective concentrations (MEC) or lethal concentrations (LC50) for this compound are not uniformly reported in accessible literature.
- **No Commercial Supplement Form Available**: This compound is not currently available as a dietary supplement, nutraceutical product, or over-the-counter preparation; it exists solely as a research chemical or phytochemical isolate.

Synergy & Pairings

No formal synergy studies have been conducted for 4,5-diethyl-3′-ethoxy-pyroflavone in combination with other compounds; however, based on the broader pharmacology of antifilarial agents, combination with ivermectin or albendazole (standard-of-care antifilarials) could theoretically produce additive or synergistic parasite-killing effects if the flavone operates through a mechanistically distinct pathway such as oxidative stress induction rather than tubulin disruption or chloride channel modulation. Within the Vitex negundo phytochemical context, the compound may act synergistically with co-isolated iridoids such as agnuside and aucubin, which contribute anti-inflammatory activity that could reduce the immunopathological burden of filarial infection alongside direct antiparasitic activity. Formulation with phospholipid complexes (phytosomes) or cyclodextrin encapsulation could enhance the bioavailability of this lipophilic flavone, indirectly amplifying its biological effect at lower administered doses.

Safety & Interactions

No formal toxicological studies, safety pharmacology assessments, or human adverse event data are available in published literature for 4,5-diethyl-3′-ethoxy-pyroflavone, making a definitive safety profile impossible to establish at this time. Given its structural classification as an alkylated and alkoxylated flavone analog, theoretical concerns include hepatotoxic potential from alkyl chain metabolites, inhibition of cytochrome P450 enzymes (particularly CYP1A2, CYP3A4) that could precipitate pharmacokinetic drug-drug interactions with anticoagulants, immunosuppressants, or antiretroviral medications, and possible hormonal activity given the structural similarity of some flavones to phytoestrogens. Contraindications have not been formally defined; however, standard precautionary guidance for uncharacterized phytochemical isolates advises against use in pregnancy, lactation, pediatric populations, or individuals with hepatic impairment until safety data are available. The absence of safety data is a critical gap that must be addressed before any consideration of human administration outside of strictly regulated clinical research settings.